Rationale Mephedrone (4-methylmethcathinone) is a still poorly known drug of abuse, alternative to ecstasy or cocaine.
Introduction
Mephedrone is a synthetic ring-substituted cathinone closely related to the phenethylamine family, differing only by a keto functional group at the beta carbon. It can be purchased online or from street dealers. On the Internet, mephedrone is often marketed as "plant food," "bath salts," or "research chemical." The rapid rise in the popularity of mephedrone may reflect growing user dissatisfaction with the purity and availability of MDMA (ecstasy) or its chemical precursors and cocaine. Mephedrone appears to be used by several population groups, including people involved in the dance and music scene as well as mainstream young adults and adolescents (Schifano et al. 2011) .
Mephedrone is known to have similar effects to other psychostimulant drugs (Brunt et al. 2012; Varner et al. 2013 ). There are two reported fatalities in the European Union in which mephedrone appears to be the sole cause of death, and there are at least another 37 deaths in which mephedrone has been detected in postmortem samples (Maskell et al. 2011) .
Mephedrone was the first cathinone derivative to be "riskassessed" by the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction.
Information on mephedrone human pharmacokinetics is limited to user reports. From these, it appears that both the desired and adverse effects of mephedrone are similar to those found for MDMA and cocaine (Wood et al. 2010b ). However, its relatively short duration of action, which leads to repeated dosing, is more similar to cocaine (Wilkinson et al. 1980) . In a recent study, 70 % of mephedrone users reported to be using it by nasal insufflation, while 30 % admitted to be taking it orally (Dickson et al. 2010; Winstock et al. 2011 ). There are numerous reports of individuals using mixed routes during a single session. Moreover, there are increasing reports of intravenous injection, and there is also one case report from the UK of an individual who developed acute mephedrone toxicity after an intramuscular injection of dissolved powder (Wood et al. 2010a) .
Users report on Internet forums that the desired effects are typically seen within 15-45 min after oral ingestion and stated that the onset of action is slower when mephedrone is taken orally on a full stomach. Users also report onset of action to be within a few minutes following nasal insufflation, with peak desired effects after 30 min. The desired effects last approximately 2-3 h; this leads users to redose during a single session to extend the duration of the desired effects.
Studies on the pharmacokinetics of mephedrone in rats are very scarce. Meyer et al. (2010) suggested that the most probable metabolites of mephedrone are present in the urine. In this study, mephedrone was administered orally and urine was collected over a 24-h period. Hadlock et al. (2011) assessed mephedrone concentrations in rat brain and plasma 1 h after binge treatment and more recently (Khreit et al. 2013 ) investigated the in vitro metabolism of mephedrone in rat-isolated hepatocytes.
The current studies were designed to investigate the pharmacokinetic profile and pharmacodynamic response to mephedrone in rats after its acute administration by intravenous and oral route at different doses using a highly sensitive and specific analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results from this study might provide useful tools in order to design new animal models of mephedrone addiction and toxicity. This objective was first pursued by constructing a pharmacokinetic/pharmacodynamics (PK/PD) model for mephedrone in rats in order to obtain basic guidelines for human risk assessment. In this study, the following main pharmacokinetic parameters were estimated: total area under the curve (AUC 0-∞ ), apparent volume of distribution at steady state (V ss ), total plasma clearance (Cl p ), metabolic clearance (Cl met ), and elimination half-life (t 1/2β ). The pharmacodynamic studies described herein focused on the evaluation of the psychostimulant effect of this drug of abuse, trying to establish a correlation between the hyperlocomotion induced by mephedrone and its plasma levels. Furthermore, other goals of this study were to analyze the metabolic pathway of mephedrone and its brain concentration after an oral administration as well as to establish a relationship between mephedrone brain concentration and its psychostimulant effect.
Materials and methods

Drugs
Pure racemic mephedrone and methylone HCl were synthetized and characterized by us as described previously (López-Arnau et al. 2012) . Mephedrone solutions for injection were prepared in saline immediately before administration. Isoflurane was from Laboratorios Dr. Esteve (Barcelona, Spain). Reagents required for LC-MS assays were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Animals
The experimental protocols for the use of animals in this study were approved by the Animal Ethics Committee of the University of Barcelona, following the guidelines of the European Community Council (86/609/EEC). Male Sprague-Dawley rats (Janvier, Le Génest, France) weighing 225-250 g were used. Animals were housed at 22±1°C under a 12-h light/dark cycle with free access to food and drinking water.
Pharmacokinetic experiments
For intravenous pharmacokinetic analysis, mephedrone was administered at a dose of 10 mg/kg. For oral pharmacokinetic experiments, mephedrone was administered at doses of 30 and 60 mg/kg to rats previously fasted for 18 h. A total of seven to nine animals per dose were used.
Blood samples (150-200 μl) were collected from isoflurane-anesthetized rats through a venipuncture of the external jugular vein in a time schedule from 0.08 to 9 h and transferred to 1-ml glass tubes (containing 10 μl EDTA 20 mg/ml) on ice. A total of four to five blood samples were obtained from one animal. After each blood extraction, an equal volume of sterile saline was infused to maintain volume and osmotic homeostasis. In some animals, blood samples were obtained 45 min after oral administration (dose of 30 mg/kg), followed by decapitation and removal of the whole brains. Blood samples from these animals were also used to perform protein binding studies.
Blood samples were centrifuged at 1,000×g for 10 min to obtain the plasma. Of the plasma samples, 90 μl was mixed with 10 μl of internal standard (IS) solution (methylone, 200 ng/ml). The mixture was extracted by adding 250 μl of methanol up to a final concentration of 70 %. The denatured proteins were precipitated by centrifugation at 10,000×g for 5 min. Of the clear supernatant, 250 μl was acidified with formic acid (50 %, v/v) to a pH of 2.5-3.0 to obtain stable extracts because in nonacidified live blood extracts, cathinones degraded relatively fast (Sørensen 2011) . The mixture was transferred to an ultrafiltration filter cup and high-molecular-weight components were removed by means of filtration through a 30-kDa regenerated cellulose membrane (Microcon 30®, Millipore, Bedford, MA, USA). The ultrafiltration unit was centrifuged at 20,000×g for 10 min and 100 μl of the filtrate was transferred to an autosampler vial.
An HP Agilent Technologies 1100 LC system equipped with an autosampler and a column oven set to 40°C and coupled API 3000 triple-quadrupole MS (AB Sciex) with a turbo ion spray source was used to quantify the corresponding cathinone. Chromatographic separation was achieved on a Luna HST C18 (100×2-mm i.d., 2.5 μm) column and controlled by Analyst software. The mobile phase was water (A) and methanol (B) with 0.1 % of formic acid in both solvents. An increasing linear gradient (v/v) of B was used (t(min), %B) as follows-(0, 5), (20, 95) , (22, 95), (22.5, 5) , and (32.5, 5)-at a constant flow rate (150 μl/min). The biological samples were refrigerated at 4°C in the autosampler and 5 μl was injected into the LC-MS/MS system. The LC-electrospray ionization (ESI)-MS/MS conditions were optimized by direct infusion of cathinone standards (1 μg/ml) dissolved in 50:50 (v/v) water (0.1 % formic acid)/methanol (0.1 % formic acid) into the MS at a constant flow rate (5 μl/min). The turbo ion spray source was used in positive mode with a capillary voltage of +4,500 V and N 2 as the nebulizer gas . For mephedrone, one transition was followed (m/z 178.1→160.0, collision energy of 17 V). Two transitions were followed for methylone (m/z 208.1→190.1 and 208.1→160.0, collision energies of 17 and 22 V respectively), and both were used for the quantification.
Blood metabolite determination
Blood samples were collected at 30, 60, and 120 min after oral administration at a dose of 30 mg/kg. The metabolite samples were treated as described above, without IS. For the metabolite identification, a Linear Trap Quadrupole Orbitrap Velos MS equipped with an ESI source was used, coupled to an Accela chromatograph, a refrigerated autosampler, and a photodiode array detector (Thermo Scientific, Hemel Hempstead, UK). Chromatographic separation was achieved on a Luna C18 (100×2.1-mm i.d., 3 μm) column. The mobile phase was the same as the one used in the pharmacokinetic studies, with an increasing linear gradient (v/v) of B (t(min), %B) as follows-(0, 2), (20, 95), (22, 95), (25, 2), and (30, 2)-at a constant flow rate (150 μl/min). The injection volume was 10 μl. Data were acquired in Fourier transform mass spectrometry mode. Operation parameters were as follow: source voltage, 3.5 kV in positive or negative ion mode; S-Lens RF levels, 60 %; capillary temperature was fixed at 275°C; sheath gas, 40 arbitrary units; and auxiliary gas, 10 arbitrary units. MS 2 acquisition was carried out using collision energy between 35 and 50 %.
Protein binding and brain levels
In protein binding experiments, samples were divided into two. One half was filtered through centrifugal filter units (Centrifree YM-30, Millipore) for comparison with the other unfiltered half. Plasma samples were extracted as described above. The extraction of brain samples was carried out as described by Hadlock et al. (2011) , and brain mephedrone levels and protein binding assays were quantified as described in the pharmacokinetic experiments.
Calibration
The plasma and brains from untreated rats were used to obtain the calibration curves. In the plasma analysis, seven standards were prepared daily in 100 μl of blank plasma (from 10 to 6,000 ng/ml). To determine brain mephedrone levels, five standards were prepared, also daily, in 0.5 ml of brain homogenate (from 10 to 250 ng/ml). Methylone was used as the IS at the final concentration of 200 ng/ml for plasma levels and 50 ng/ml for brain levels. The method showed linearity within the concentration range studied, and the limit of quantification was considered lower than 10 ng/ml. Quality control samples were prepared at 50, 1,000, and 5,000 ng/ml for plasma and 20, 50, and 200 ng/ml for brain analyses. The accuracy of the assay was 90-110 % and the intra-and inter-assay coefficients of variation (CV) were <15 %.
Locomotor activity experiments
Prior to experiments, animals received two habituation sessions (48 and 24 h before testing). During these sessions, each rat was intravenously or orally administered saline and placed in a Plexiglas cage. This cage constituted the activity box that was later placed inside a frame system of two sets of 16 infrared photocells (LE8811, PANLAB, Barcelona, Spain) mounted according to the x-and y-axis coordinates and 2.5 cm above the wire mesh floor. Occlusions of the photo beams were recorded and sent to a computerized system (SedaCom32, PANLAB). The interruption counts, over a 10-min block, were used as a measure of horizontal locomotor activity. After intravenous or oral drug administration, locomotor activity was monitored for 180 and 240 min, respectively. On the testing day, the animals received mephedrone intravenously (10 mg/kg) or orally (30 or 60 mg/kg) and were immediately placed in the activity box. Registration of horizontal locomotor activity then began.
Pharmacokinetic/pharmacodynamic modeling PK/PD analysis was carried out on mean and standard deviation data. Because experimental data were obtained in parallel assays, data fitting was performed with the aggregates of the different doses (data pooling) in order to estimate a unique set of parameters. Assessment of the relative goodness of fit of each proposed model to the observed data was based on the objective function value, the Akaike's information criterion (AIC), the residual and weighted residual plots, and the errors in parameter estimation, expressed as the CV (in percent). PK and PK/PD analyses were achieved using the compartmental modeling SAAM II software system (SAAM Institute, Seattle, WA, USA).
Pharmacokinetic analysis
The distribution and elimination characteristics of mephedrone were determined after i.v. administration. Fixing the parameters obtained in the i.v. model, 30 and 60 mg/kg (p.o.) mephedrone profiles were analyzed simultaneously using a bicompartmental model with oral delay and Michaelis-Menten metabolism kinetics. The best-fit line was selected after visual inspection of the fitting, the analysis of the objective function and the AIC, the precision of the estimates (mean and CV), and the weighted residual plot analysis.
The i.v. data were described by an open two-compartment model and fit to the following equation:
where C p is the total plasma drug concentration at time t, the terms A and B are the extrapolated zero intercepts, and α and β represent the apparent first-order elimination rate constants. The half-life (t 1/2β ) for the elimination phase and the volume of distribution in the central compartment (V c ) were calculated as follows: t 1/2β =0.693/k 10 , where k 10 is an overall elimination rate constant,
For the oral route, an absorption rate constant, k a , was fitted. The area under the concentration-time curve (AUC 0-∞ ) and area under the first moment of the plasma drug concentration-time curve (AUCM 0-∞ ) were calculated using the following equations:
The values reported as the C max and T max are the actual observed values. The F (bioavailability) value for oral administration can be calculated using the following formula:
where, for the oral and i.v. routes, D oral and D iv are the respective doses; AUC 0-∞ oral and AUC 0-∞ i.v. are the respective AUCs from 0 to infinity. Oral pharmacokinetics parameters were calculated with the following equations:
where k a and t 1/2,abs are the absorption constant and the absorption constant half-life obtained after oral administration, respectively. MRT and MAT are the mean resident time and the mean absorption time, respectively. The microconstants k 12 and k 21 used for the calculation of V ss are the terms that describe the distribution of the drug between the central and peripheral compartments. When Michaelis-
Menten fitting was applied, the first-order elimination constant from the central compartment was substituted by the following equation:
where C t is the mephedrone concentration at time t, V max the maximum metabolic capacity achieved by the metabolic system, and K m the Michaelis-Menten constant. Cl met is the metabolic clearance calculated as follows (Barrett et al. 1998) :
Pharmacokinetic/pharmacodynamic analysis A link compartment representing stimulation of the locomotor behavior was used to describe the data (Sheiner et al. 1979) . Integration of mephedrone pharmacokinetics and pharmacodynamics was based on the relationship between mean plasma mephedrone concentration-time profiles for i.v. and oral dosages. PK/PD modeling was also performed using SAAM II. The effect site was connected by a fixed rate constant from the central plasma compartment. A dummy compartment provides the concentrations in the effect site (C e ). The stimulation PK/PD model proposed by the sigmoid E max equation is expressed in terms of C e such that
The baseline value E 0 is the effect when mephedrone concentration is zero. EC 50 is the concentrations that increase E 0 to 50 % of the E max or maximal response, and "n" determines the sigmoid shape of the function (Hill coefficient) and contributes to the steepness of the slope. This produces a PD model that describes the effect as a function of time.
Results
Mephedrone pharmacokinetics
The observed plasma concentrations after i.v. administration of mephedrone at each time point are shown in Fig. 1 . Plasma mephedrone was almost undetectable at 4 h after administration of this dose. Estimated values for the main pharmacokinetic parameters of intravenous administration in rats are presented in Table 1 .
The plasma concentrations versus time curves after intravenous administration of mephedrone were described by a two-compartment model with a significantly different distribution and terminal elimination phases (α=10.23 h −1 , β= 1.86 h −1 ). The pharmacokinetic parameters showed that t 1/2β was 0.37 h. Cl p and V ss were 1.69 l/h and 2.60 l/kg, respectively (Table 1) . For oral dosing conditions, the pharmacokinetic parameters derived from the mephedrone plasma concentration curves are summarized in Table 2 . C max values were achieved rapidly, showing a T max within 0.43-0.93 h; the plasma concentrations declined to undetectable levels at 9 h. Dose-normalized C max at 60 mg/kg (16.00±5.70) was greater than that observed at 30 mg/kg (11.00± Fig. 1 Semi-logarithmic plot of the experimental and fitted mephedrone plasma levels after intravenous (10 mg/kg) and oral (30 and 60 mg/kg) administrations. Rats received mephedrone at time 0 and blood specimens (0.2 ml) were collected through the external jugular vein from 0.08 to 8 h after administration. Mephedrone plasma levels were quantitated by LC-MS as described in "Materials and methods." Data are the mean for n=4-5 rats/group (Table 2) . After oral administration, the value of Cl met decreased from 77 % of total plasma clearance (at the dose of 30 mg/kg) to 20 % (at the dose of 60 mg/kg), showing an oral dose-dependent kinetic behavior.
Mephedrone protein binding and brain levels
Results from the present assays evidenced a percentage of mephedrone protein binding of 21.59±3.67 %. Brain levels of 104.4±17.7 ng mephedrone per gram tissue (n=3) were found. A relationship between brain levels and free plasma concentration yielded a ratio of 1.85±0.08.
Identification of mephedrone and metabolites in rat blood
We have identified five metabolites of mephedrone. These metabolites were detected in all collected samples at 30, 60, and 120 min. A description of the identification of mephedrone and the observed metabolites is provided below. ) yielded a fragment with low intensity at m/z147. The presence of the fragment at m/z119 indicates the loss of C 3 H 9 N (59 Da), the intensity of which was found to be considerably low.
Mephedrone
4-Methylcathinone
We identified the corresponding N-demethylation metabolite, 4-methylcathinone, with formula C 10 H 13 NO. ] m/z was 164.10728 (0.29 mDa). The peak at m/z146 corresponds to H 2 O loss (18 Da). C 2 H 6 N loss (45 Da) gave a peak at m/z119. Both losses suggest that this mass spectrum is in accordance with the metabolite structure proposed.
4-Hydroxymethylmethcathinone
We identified an allylic hydroxylation of mephedrone, the resulting chemical formula of which was C 11 H 15 11 mDa) . The typical loss of water was also observed, giving a peak at m/z176. Furthermore, we detected a double water loss (36 Da), suggesting the possible presence of a hydroxyl group in this structure. The loss of C 3 H 9 N gave a peak at m/z135, indicating that this fragment contains the hydroxyl group previously mentioned. Moreover, the double loss of water leads us to conclude that this group can only be found in the allylic position (Fig. 2) .
4-Carboxymethylmethcathinone
The structure corresponding to the oxidation of 4-hydroxymethylmethcathinone was identified; the chemical formula for this compound was C 11 H 13 ] m/z was 208.09702 (0.35 mDa). In positive ion mode, the spectrum showed a peak at m/z149 (C 3 H 9 N loss), indicating the possible presence of a carboxybenzoyl cation fragment. The detection of a typical carboxylic loss (44 Da) in negative ion mode confirmed the proposed structure. water was also observed, giving a peak at m/z 176. Additionally, double loss of water (36 Da) was detected, indicating the possible presence of a hydroxyl group in this structure. Loss of the methylbenzoyl cation fragment (119 Da) gave a peak at m/z74, which corresponds to a hydroxylated immonium cation, thus confirming the proposed structure.
3′-Hydroxy-4-methylmethcathinone
?-Hydroxy-4-methylmethcathinone
The metabolite corresponding to an aromatic hydroxylation for mephedrone was detected. The chemical formula for this structure was also 18 mDa) . The peak at m/z 135 corresponds to the hydroxylated methylbenzoyl cation, and the single loss of water (peak at m/z 176) suggests that this group is in an undetermined aromatic position.
We ensured that the mass found did not correspond to endogenous compounds by comparing each metabolite mass from the treated and untreated rat blood samples. Based on the found metabolites, we propose the following phase I metabolic pathway for mephedrone, displayed in Fig. 3 .
Locomotor activity
Intravenous administration of mephedrone induced a significant increase in rat locomotor activity (AUC: saline, 8683± 98; mephedrone, 71248±9518; n=3, p<0.01, independent samples Student's t test) that lasted for 120 min.
Similarly, an overall ANOVA demonstrated a significant effect of oral mephedrone on the locomotor activity in rats (F 2,8 =11.261, p<0.01). Post hoc Tukey-Kramer tests revealed that oral administration of mephedrone increased the locomotor activity in a dose-dependent manner (AUC: saline, 20,760 ± 2,002; mephedrone 30 mg/kg, 39,778 ± 10,255, p<0.05; mephedrone 60 mg/kg, 79,692±22,302, p<0.01; n=3); 60 min after the dose of 30 mg/kg breaks, values were not significantly different from animals treated with saline. At the dose of 60 mg/kg, the psychostimulant effect of mephedrone persisted for 90 min (Fig. 4) .
Pharmacokinetic/pharmacodynamic analysis A plot of locomotor activity versus mephedrone concentrations over time shows a direct concentration-effect relationship after i.v. administration (Fig. 5a ). After oral dosing (Fig. 5b, c) , a clockwise hysteresis loop was observed, mainly with the highest dose. The model shows a mean E max value of Table 3 ). Good agreement between the predicted and observed values was obtained in accordance with the quality model adequacy (mean objective function=4.35, AIC=9.54, determined CV <50 % for all the estimated parameters).
Discussion and conclusions
The pharmacokinetics of mephedrone was investigated in adult male Sprague-Dawley rats. In this study, the increase in locomotor activity induced by mephedrone after i.v. and oral administration was characterized and an integrated PK/PD model was provided.
A significant increase in locomotor activity (a measure of psychostimulant effects) occurred after mephedrone administration and is consistent with the onset of subjective effects in humans. The doses reported vary from 15 to 250 mg for oral ingestion and from 5 to 125 mg for nasal insufflation, with total doses typically ranging 0.5-2.0 g after redosing during a Fig. 3 In vivo metabolic pathways proposed for mephedrone in rat plasma after a single oral administration of 30 mg/kg Fig. 4 Time course of locomotor activity induced after oral (30 and 60 mg/kg) and intravenous (10 mg/kg) administrations of mephedrone. For this behavior, the interruption counts were registered, displayed in a 30-min block. Vertical axis shows breaks per animal in 30-min intervals. Locomotor activity was monitored for 240 and 180 min for oral and intravenous administrations, respectively. Data are expressed as the mean±SEM values from three rats single session. The oral doses used in this study were chosen according to Internet information (http://www.erowid.org, last accessed March 1, 2013) and the literature (Simmler et al. 2013) . These doses were calculated following the FDA guidelines (Food and Drug Administration Center for Drug Evaluation and Research 2005) and are equivalent to 336 and 672 mg, respectively.
The pharmacokinetics of mephedrone in plasma after i.v. and oral administrations was well described by a twocompartment open model with and without MichaelisMenten elimination, respectively. The goodness of fit and the quality of the estimated pharmacokinetic parameters were evaluated and confirmed by the objective function, AIC, plot of observed versus predicted concentrations, and the variation coefficients with values <50%, except for the V max value at the highest oral dose where the CV has not been estimated.
Our results show that the blood levels of mephedrone declined biphasically after intravenous administration. The large apparent V ss indicates that, in rats, mephedrone is distributed extensively into tissues. This V ss value was expected of a highly lipophilic molecule that must cross the blood-brain barrier in order to exert its psychostimulant effect.
Compounds with a brain/plasma ratio value >1 freely cross the blood-brain-barrier (Hitchcock and Pennington 2006) . The obtained value of mephedrone brain/plasma ratio of 1.85 indicates low brain penetrance when compared to amphetamine-like compounds (Chu et al. 1996) and may explain why mephedrone, compared to MDMA, is a weak motor stimulant, causes weak hyperthermia, and induces minor changes in brain monoamines (Baumann et al. 2012) .
Comparing the two oral doses, an evident non-linearity in the pharmacokinetics of mephedrone was detected using a Michaelis-Menten elimination equation. The nonlinear pharmacokinetics described in the study allows identifying different V max and K m values, suggesting that the pathways involved in the metabolic clearance may be quantitatively and/or qualitatively different depending on the dose. Because the metabolic clearance decreased from 77 % of the total plasma clearance (at the dose of 30 mg/kg) to 20 % (at the dose of 60 mg/kg), and taking into account the presence of phase I metabolites in plasma, a possible saturation of liver metabolic enzymes and pathways is suggested. These results are in agreement with the low oral bioavailability observed and suggest that mephedrone undergoes an extensive first-pass effect after oral administration. Moreover, it is important to note that the low bioavailability of mephedrone explains its widespread use snorted rather than taken orally.
This study represents the first qualitative assessment of mephedrone metabolites in rats after oral intake. We identified the presence of five metabolites in rat blood at three time points after administration (30, 60, and 120 min) . Based on the obtained data, we propose a first step of phase I metabolism for mephedrone, implying an N-demethylation reaction, yielding the corresponding methylcathinone metabolite. Mephedrone undergoes different oxidative reactions including aliphatic and aromatic hydroxylation, leading to the corresponding 3′-hydroxy-methylmethcathinone or ?-hydroxy-4-methylmethcathinone metabolites. Khreit et al. (2013) proposed one of these metabolites as an unidentified compound named "compound U." This is the first time that both mephedrone metabolites have been identified in vivo. We also identified 4-hydroxymethylmethcathinone, a metabolite resulting from an allylic hydroxylation of mephedrone, which would subsequently suffer an oxidation, leading to the final metabolite 4-carboxymethylmethcathinone.
Intravenous and oral administrations of mephedrone induced a psychostimulant effect, measured as an increase in the locomotor activity in male Sprague-Dawley rats. As we have described previously in mice (López-Arnau et al. 2012) , after oral administration to rats, a dose-dependent duration of the effect of mephedrone was found.
Mephedrone blocks [ 3 H]DA into neurons (Cozzi et al. 1999; Hadlock et al. 2011; Nagai et al. 2007; López-Arnau et al. 2012) . Our previous studies in brain synaptosomes demonstrated that the inhibition of this transporter by mephedrone is the result of a direct interaction with these proteins, competing with the endogenous substrate (López-Arnau et al. 2012 ). This contrasts with our findings in mephedrone on the 5-HT transporter . For this compound, a difference was found between the IC 50 value of the inhibition of [ 3 H]5-HT uptake and the K i value for the interaction with the 5-HT transporter, suggesting an additional mechanism rather than a direct interaction with the transporter. Similar to amphetamines, the action of mephedrone is not a mere inhibition of the uptake transporter. Baumann et al. (2012) demonstrated that mephedrone evoke a transporter-mediated release of monoamines via reversal of the normal transporter flux. The authors concluded that mephedrone is a substrate for noradrenaline and DA transporters, with slightly lower potency at the 5-HT transporter.
The lower values of EC 50 obtained in release experiments versus those obtained in uptake inhibition allows deducing that the release phenomena are predominant versus the uptake inhibition.
Although more research on the pharmacology and toxicology of abused cathinones is needed (Baumann et al. 2013) , this study shows new insights into the pharmacokinetic-pharmacodynamic relationship of mephedrone. The naive pool data used in the study do not allow the estimation of variation within and between subjects because the collection of data from single individuals yields information that is lost when analyzing pooled data. Between-subject variability information for each dose is lost when naive pool concentration data are used, and when pharmacodynamics results were obtained from rats without pharmacokinetic information, the within-subject variability of PK/PD parameters cannot be estimated. Despite these constraints, the model built in the study allows using it as a useful tool for the PK/PD relationship understanding of mephedrone in our experimental conditions. By means of pharmacokinetic-pharmacodynamic relationship, it is possible to perform an estimation of the EC 50 in the effect compartment and E max parameters as well as an evaluation of the onset, magnitude, and time course of the psychostimulant effect. The pharmacodynamics maximum effect was observed immediately after mephedrone administration, and the decay of the stimulatory effect was evaluated from the plot of locomotor activity as a function of mephedrone plasma concentrations.
After i.v. administration, the change in response was directly interpretable as a function of mephedrone concentration with the use of a sigmoidal E max model (Csajka and Verotta 2006) . After oral dosage, plots of mephedrone effect versus observed plasma mephedrone concentrations revealed a clockwise hysteresis loop in both oral dosages. A clockwise hysteresis loop has been described after cathinone (Schechter 1990) or MDMA administration (Hysek et al. 2012) and could be attributable to the more rapid distribution of the drug to the brain than to venous blood (Porchet et al. 1987) .
The brain/plasma ratio obtained in this study suggests that mephedrone freely crosses the blood-brain barrier, showing an appreciable distribution within the brain. Previous in vitro results suggest that mephedrone inhibits dopamine, norepinephrine, and serotonin uptake at concentrations around 1 μM (López-Arnau et al. 2012) . These results are in close agreement with the EC 50 values in the effect site calculated in the present study by means of the proposed PK/PD model. The low bioavailability of mephedrone found after oral ingestion justifies why abusers preferably snort it. Mephedrone's half-life is shorter than that of MDMA (Fonsart et al. 2009 ), which causes users to often redose, thus contributing to the appearance of addiction. Finally, the nonlinear kinetics after oral administration of mephedrone can cause a dramatic increase in plasma levels, leading to enhanced toxicity.
In conclusion, the present research provides, for a first time, useful information on the in vivo pharmacokinetics, pharmacodynamics, and the pharmacokinetic-pharmacodynamic relationship of mephedrone in rats and will help design new experiments in rodents with kinetics-based data as well as offer a better understanding of the effects of this drug of abuse in humans.
